Abatacept: Pricey, but Effective
Abatacept: Pricey, but EffectiveThe approval of abatacept (Orencia/Bristol-Myers Squibb) for psoriatic arthritis (PsA) earlier this month by the FDA offers a new treatment option for patients who are struggling to keep the disease under control.
Study: Little difference in shingles risk among RA biologicsResults of a new study suggest that no matter what biologic they are treated with, older patients with rheumatoid arthritis face pretty much the same risk of developing herpes zoster.